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Abstract For the five principal prostanoids PGD2, PGE2,
PGF2K, prostacyclin and thromboxane A2 eight receptors have
been identified that belong to the family of G-protein-coupled
receptors. They display an overall homology of merely 30%.
However, single amino acids in the transmembrane domains such
as an Arg in the seventh transmembrane domain are highly
conserved. This Arg has been identified as part of the ligand
binding pocket. It interacts with the carboxyl group of the
prostanoid. The aim of the current study was to analyze the
potential role in ligand binding of His-81 in the second
transmembrane domain of the rat PGF2K receptor, which is
conserved among all PGF2K receptors from different species.
Molecular modeling suggested that this residue is located in close
proximity to the ligand binding pocket Arg 291 in the 7th
transmembrane domain. The His81 (H) was exchanged by site-
directed mutagenesis to Gln (Q), Asp (D), Arg (R), Ala (A) and
Gly (G). The receptor molecules were N-terminally extended by
a Flag epitope for immunological detection. All mutant proteins
were expressed at levels between 50% and 80% of the wild type
construct. The H81Q and H81D receptor bound PGF2K with
2-fold and 25-fold lower affinity, respectively, than the wild type
receptor. Membranes of cells expressing the H81R, H81A or
H81G mutants did not bind significant amounts of PGF2K. Wild
type receptor and H81Q showed a shallow pH optimum for
PGF2K binding around pH 5.5 with almost no reduction of
binding at higher pH. In contrast the H81D mutant bound
PGF2K with a sharp optimum at pH 4.5, a pH at which the Asp
side chain is partially undissociated and may serve as a hydrogen
bond donor as do His and Gln at higher pH values. The data
indicate that the His-81 in the second transmembrane domain of
the PGF2K receptor in concert with Arg-291 in the seventh
transmembrane domain may be involved in ligand binding, most
likely not by ionic interaction with the prostaglandin’s carboxyl
group but rather as a hydrogen bond donor.
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1. Introduction
Prostanoid receptors are ectoreceptors with seven trans-
membrane spanning domains that couple to heterotrimeric
G-proteins [1]. One receptor each exists for the prostanoids
PGD2 (DP-R), PGF2K (FP-R), prostacyclin (IP-R) and
thromboxane A2 (TP-R), while four types of receptors are
known for PGE2 (EP1-R to EP4-R) [2]. The di¡erent prosta-
noid receptors couple to di¡erent G-proteins: FP-R, EP1-R
and TP-R couple to Gq and increase InsP3 and hence cyto-
solic Ca2, DP-R, EP2-R, EP4-R and IP-R couple to Gs and
increase intracellular cAMP while EP3-R couples to Gi and
decreases hormone-stimulated cAMP formation. The di¡erent
prostanoid receptors display an overall sequence homology of
merely 30%, yet some amino acids, especially in the putative
transmembrane domains, are highly conserved [3]. Analysis of
naturally occurring splice variants [4,5], of receptor hybrids
[6^9] and of receptors in which single highly conserved amino
acids had been exchanged by site-directed mutagenesis [10,11],
has provided some insight into the structure-function relation-
ship of prostanoid receptors. While the intracellular C-termi-
nal domain has been implicated in G-protein coupling control
[6,8] and agonist-induced receptor desensitization [7,9], amino
acids in the transmembrane domains and the extracellular
loops have been shown to be responsible for high a⁄nity
ligand binding and ligand speci¢city: all EP-R have a com-
mon sequence in the second extracellular loop, which is absent
from any other prostanoid receptor and confers the speci¢city
towards PGE2 [12]. The seventh, sixth and third transmem-
brane domains have been implicated in ligand binding by
analysis of hybrid receptors between IP-R and DP-R [8]. An
Arg in the seventh transmembrane domain, which is con-
served among all prostanoid receptors, has been shown to
be essential for high a⁄nity ligand binding in the EP3-R
[13] and TP-R [14].
Other conserved polar amino acids in the otherwise apolar
transmembrane domains are likely potential candidates for
interaction with the prostanoid ligand. These include Asp
and Thr in the second, a Gln in the ¢fth, a Cys in the sixth
and an Asp in the seventh transmembrane domain which are
conserved among all rat prostanoid receptors so far cloned. In
the rat FP-R (rFP-R) there is a His-81 in the second trans-
membrane domain which is conserved among all FP-Rs from
di¡erent species. Molecular modeling (see below) has revealed
that this residue may be located in close proximity to the
ligand binding pocket Arg-291 in the seventh transmembrane
domain and might, thus, participate in PGF2K binding. It was
the purpose of the current study to analyze a possible role of
this histidyl residue for high a⁄nity PGF2K binding.
2. Materials and methods
2.1. Materials
All materials were of analytical grade and from commercial sources.
[3H]PGF2K was obtained from Amersham (Braunschweig, Germany),
unlabeled PGF2K was purchased from Calbiochem-Novabiochem
(Bad Soden, Germany). Cell culture media were from Gibco-BRL
(Eggenstein, Germany) and primers (Table 1) were synthesized by
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NAPS (Goºttingen, Germany). The monoclonal antibody FLAG-M2
was obtained from Sigma (Heidelberg, Germany). The sources of
other materials are given in the text.
2.2. Cloning of the rat hepatocyte FP-R and computer-directed
modeling of three-dimensional receptor conformation
The cDNA for the rFP-R was cloned from rat hepatocyte cDNA
by RT-PCR. Total RNA was isolated from puri¢ed hepatocytes by
CsCl gradient centrifugation [15]. Poly(A) mRNA was prepared by
a⁄nity puri¢cation using oligo-(dT) beads from Qiagen (Rathingen,
Germany) according to the manufacturer’s instructions. First strand
cDNA was synthesized by reverse transcription using oligo-(dT)12ÿ18
(Pharmacia, Freiburg, Germany) as a primer. PCR was carried out
using 10 ng ¢rst strand cDNA as a template and the primer pair RFP-
1F and RFP-8R (Table 1). Thirty-¢ve cycles of PCR were performed
with the following temperature pro¢le: 1 min 95‡C, 1 min 57‡C and
3 min 72‡C. A 1350 bp fragment was ampli¢ed and cloned into
pUC18 (Pharmacia). Nucleotide sequence analysis was carried out
on double stranded templates using the dideoxy chain termination
method. For eukaryotic receptor expression a 1.0 kb cDNA fragment
encoding the translated region of the rFP-R was subcloned in the
eukaryotic expression vector pSVL (Pharmacia).
The seven putative transmembrane domains of the receptor were
deduced from hydropathy analysis according to Kyte and Doolittle.
The sequences were entered into the SWISS-MODEL Automated
Comparative Protein Modeling Server in the GPCR mode as follows:
helix 1: 28LSVFFSIIFMTVGIVSNSLAIAILM; helix 2: 66FLLLA-
SGLVITDFFGHLINGGIAVF; helix 3: -109SVFGISMVFSGLCP-
LFLGSTMAI-; helix 4: - -154MILSGVCMFAVFVALLPILGH- -;
helix 5: 203LFFSSLGLLALGISFSCNAVTGVTL; helix 6: -248VIQ-
LLAIMCVSCVCWSPFLVTMA-; helix 7: -285TTLFALRMATWN-
QILDPWVY ILL-. The topology was calculated with the human
NPY receptor as template.
2.3. Site-directed mutagenesis and attachment of a N-terminal
Flag-epitope tag
A Flag octapeptide sequence (N-Asp-Lys-Tyr-Asp-Asp-Asp-Asp-
Lys-C) recognized by the monoclonal antibody FLAG-M2 was in-
serted after the initiator methionine of the rFP-R by PCR using Silver
Star Taq polymerase (Eurogentec, Seraing, Belgium). The forward
primer was FLAG-FP-F (Table 1), which starts at the second trans-
lated codon of the rFP-R and possesses a 5P overhanging sequence
encoding a XhoI site, a Kozak sequence and a Flag tag. The reverse
primer was FP-Xba-R. It is located in the 3P-UTR of the rFP-R
cDNA and it encodes an XbaI site (Table 1). The PCR was performed
with 10 ng template (pSVL/rFP-R) and 35 cycles of the following
temperature pro¢le: 1 min 95‡C, 1 min 60‡C and 2 min 72‡C. The
PCR product was puri¢ed, digested with XhoI and XbaI and then
ligated into the XhoI/XbaI site of the eukaryotic expression vector
pSVL (Pharmacia).
Mutation of the His-81 of the rFP-R was performed by PCR-based
site-directed mutagenesis using Silver Star Taq polymerase, pSVL/
FLAG-rFP-R as template and the following PCR program: 3 min
95‡C, 35U(1 min 95‡C, 1 min 55‡C, 2 min 72‡C), 10 min 72‡C. For
each mutant two overlapping PCR products containing the mutation
in the overlap region were synthesized and then fused by a subsequent
PCR with the two £anking primers. A 296 bp 5P fragment was gen-
erated with FLAG-FP-F as a forward primer and a reverse primer
containing the H81 mutation (H81Q-R, H81D-R, H81R-R, H81G-R
or H81A-R, Table 1). A 3P 976 bp fragment was produced with the
forward primer covering the mutation site (H81Q-F, H81D-F, H81R-
F, H81G-F or H81A-F, Table 1) and the primer FP-Xba-R. A PCR
product containing the entire open reading frame was then generated
with both overlapping fragments as template and the primers FLAG-
FP-F and FP-Xba-R. The PCR product was puri¢ed and digested
with XhoI at the 5P site and BstEII at the 3P site of the mutation.
The fragment of the PCR product bearing the mutation was then
ligated into pSVL/FLAG-rFP-R in which the corresponding cDNA
fragment had been removed by digestion with XhoI and BstEII. The
sequences of the mutated cDNAs cloned into pSVL were veri¢ed by
sequencing.
2.4. Cell culture and transfection
COS-7 cells were cultured in DMEM containing 10% (v/v) FCS and
penicillin (100 U/ml) and streptomycin (100 Wg/ml) as antibiotics.
COS-7 cells were seeded at a density of 106 cells/10 cm diameter plate
and transiently transfected after 24 h using the DEAE-dextran meth-
od [16] with wild type pSVL/FLAG-rFP-R or the mutant receptor
constructs cloned into pSVL (5 Wg/plate). Assays were performed
72 h after transfection.
2.5. Membrane isolation and PGF2K binding assay
For membrane preparations, transfected cells were scraped into a
homogenization bu¡er containing 25 mM Tris-HCl pH 7.5, 250 mM
sucrose, 10 mM MgCl2, 1 mM EDTA and 0.2 mM Pefabloc SC
(Biomol, Hamburg, Germany), 10 Wg/ml leupeptin and 10 Wg/ml soy-
bean trypsin inhibitor as protease inhibitors. After homogenization of
the cells in a Dounce homogenizer a crude membrane fraction was
prepared by centrifugation of the homogenate at 100 000Ug. The
resulting pellet was suspended in binding bu¡er containing 25 mM
MES-NaOH pH 6.2, 10 mM MgCl2 and 1 mM EDTA and stored at
370‡C. To determine the pH optimum of binding below pH 5.5 MES
was replaced in the binding bu¡er by 25 mM glycine. For PGF2K
binding, membranes (20^50 Wg protein) were incubated with 5 nM
[3H]PGF2K in 100 Wl binding bu¡er for 1 h at 20‡C. Non-speci¢c
binding was determined in the presence of 10 WM PGF2K. Bound
and unbound ligand were separated by rapid vacuum ¢ltration
through GF 52 ¢lters (Schleicher and Schuºll, Dassel, Germany). Fil-
ters were washed ¢ve times with 4 ml ice-cold binding bu¡er. Radio-
activity retained on the ¢lter was counted in 5 ml Hydroluma (Baker,
Deventer, The Netherlands). Binding constants were calculated by
non-linear regression analysis (LIGAND [17]).
2.6. Protein deglycosylation with endoglycosidase F
Membrane proteins (20^50 Wg) of transfected or control cells were
solubilized with a 0.1 M sodium phosphate bu¡er pH 8.6 containing
1.2% (v/v) Nonidet-P 40, 0.2% (w/v) SDS, 2 mM EDTA, 1% (v/v)
L-mercaptoethanol and 0.2 mM Pefabloc SC, 10 Wg/ml leupeptin and
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Table 1
Oligonucleotide primers used for RT-PCR cloning and site-directed mutagenesis
Name Sequence (5PC3P) Position in GenBank (accession number X83856)
RFP-1F (forward) CTGGTTGCGCCATGGAACACCGGGC 1^25
RFP-8R (reverse) TACACACAGCGGTCCAAGTGTTCCAG 1345^1319
FLAG-FP-F (forward) gcgctcgagccaccatggactacaaggacgacgacga-
caagTCCATAAACAGTTCCAAGCAGCCG
XhoI recognition site (underlined), Kozak sequence
(bold), Flag epitope (italic) and RFP-R 152^175
FP-Xba-R (reverse) ggcgcgtctagaTACACACAGAGGTCCAAGTGT XbaI recognition site (underlined) and RFP-R 1345^
1325
H81Q-F (forward) CTTCGGCCAACTCATCAACGGAGGG 406^382 (mutation bold)
H81D-F (forward) CTTCGGCGACCTCATCAACGGAGGG 406^382 (mutation bold)
H81R-F (forward) CTTCGGCCGCCTCATCAACGGAGGG 406^382 (mutation bold)
H81G-F (forward) CTTCGGCGGCCTCATCAACGGAGGG 406^382 (mutation bold)
H81A-F (forward) CTTCGGCGCCCTCATCAACGGAGGG 406^382 (mutation bold)
H81Q-R (reverse) inverted complementary sequence of H81Q-F
H81D-R (reverse) inverted complementary sequence of H81D-F
H81R-R (reverse) inverted complementary sequence of H81R-F
H81G-R (reverse) inverted complementary sequence of H81G-F
H81A-R (reverse) inverted complementary sequence of H81A-F
M. Rehwald et al./FEBS Letters 443 (1999) 357^362358
10 Wg/ml soybean trypsin inhibitor as protease inhibitors for 1 h at
37‡C and 10 min at 60‡C under vigorous shaking. Proteins were then
deglycosylated with 0.2 U endoglycosidase F (Boehringer Mannheim,
Mannheim, Germany) for 16 h at 37‡C.
2.7. Western blotting
Membrane proteins (20^50 Wg) of transfected or control cells were
solubilized in Laemmli sample bu¡er under reducing conditions for
60 min at 37‡C and 10 min at 60‡C with vigorous shaking, separated
on 10% SDS-polyacrylamide gels and transferred to PVDF membrane
(Millipore, Bedford, MA, USA) by semi-dry blotting. The PVDF
membrane was blocked with 5% (w/v) skim milk in PBS, 0.1% (v/v)
Tween 20 (PBS-T). Flag-tagged receptor proteins were detected by
incubating immunoblots overnight with 0.3 Wg/ml monoclonal anti-
body FLAG-M2 in 1% (w/v) skim milk in PBS-T at 4‡C followed by
horseradish peroxidase-conjugated anti-mouse IgG (1:20 000 dilution,
Bio-Rad, Munich, Germany) for 60 min at room temperature. Anti-
gen-antibody complexes were visualized with the ECL system (Amer-
sham, Braunschweig, Germany) according to the instruction of the
company. To quantify receptor expression the intensity of FLAG-
FP-R bands was determined densitometrically using the ImageQuant
system (Molecular Dynamics, USA).
3. Results and discussion
3.1. Molecular modeling-based hypothesis
A cDNA for a rFP receptor was cloned from rat hepatocyte
cDNA by RT-PCR based on the known sequence of the
mouse ovary FP-R [18]. The cDNA was sequenced and the
deduced 366 amino acid peptide sequence was found to be
96% identical to the mouse FP-R and 100% identical to the
FP-R cloned from rat astrocytes [19]. Sequence homologies to
human FP-R, rabbit FP-R and bovine FP-R were 85%, 80%
an 81%, respectively. Hydrophobicity analysis according to
Kyte and Doolittle [20] revealed the existence of seven puta-
tive transmembrane domains of 21^25 amino acids in length.
The spatial arrangement of these transmembrane domains
was calculated with the SWISS-MODEL Automated Compa-
rative Protein Modeling Server in the GPCR mode [21^23]
(Fig. 1). According to this model, the second and seventh
transmembrane domains are close neighbors. Arg-291, which
is the homologue of the Arg in the ligand binding pocket of
the EP3-R and the TP-R, faces toward a cleft between the
second and the seventh transmembrane domains, which is
supposed to harbor the carboxyl group of the prostanoid.
Interestingly, in such a model the His-81 in the second trans-
membrane domain comes into close proximity to the Arg-291
in the seventh transmembrane domain both in the lateral and
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Fig. 1. Molecular modeling of a hypothetical three-dimensional ar-
rangement of the rFP-R transmembrane domains. The seven puta-
tive transmembrane domains of the receptor were deduced from hy-
dropathy analysis according to Kyte and Doolittle [20]. The
sequences were entered into the SWISS-MODEL Automated Com-
parative Protein Modeling Server in the GPCR mode as follows:
helix 1: 28LSVFFSIIFMTVGIVSNSLAIAILM; helix 2: 66FLLLAS-
GLVITDFFGHLINGGIAVF; helix 3: -109SVFGISMVFSGLC-
PLFLGSTMAI-; helix 4: - -154MILSGVCMFAVFVALLPILGH- -;
helix 5: 203LFFSSLGLLALGISFSCNAVTGVTL; helix 6: -248VI-
QLLAIMCVSCVCWSPFLVTMA-; helix 7: -285TTLFALRMATW-
NQILDPWVY ILL-. The topology was calculated with the human
NPY receptor as template.
Fig. 2. Detection of Flag-tagged rFP-R and rFP-H81Q-R by immu-
noblotting with the FLAG-M2 antibody. Membrane proteins (20^30
Wg/lane) of control and transfected cells were resolved by SDS-
PAGE without or after pretreatment with endoglycosidase F and
transferred to a PVDF membrane by semi-dry blotting. Receptor
proteins were detected with a sandwich of the monoclonal antibody
FLAG-M2 and horseradish peroxidase-conjugated anti-mouse anti-
serum visualized with enhanced chemiluminescence as described in
Section 2.
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in the vertical dimension (Fig. 1). The His-81 might thus also
participate in the interaction with the carboxyl group of the
PGF2K in the FP-R binding pocket. To substantiate this hy-
pothesis, the His-81 was exchanged to Gln, Asp, Arg, Gly and
Ala and the binding characteristics of the resulting receptor
mutants were analyzed.
3.2. Expression of the rFP-H81X receptor proteins
The codons for the His residue in the second transmem-
brane domain were replaced by codons for Gln, Asp, Arg,
Ala and Gly by site-directed mutagenesis. Additionally the
translated region of the cDNA was extended at the 5P end
by 27 nucleotides encoding a start Met and an octapeptide
that represents the epitope for the monoclonal FLAG-M2
antibody and allows the immunological detection of the mu-
tant receptor proteins. The modi¢ed cDNAs were cloned into
the eukaryotic expression vector pSVL and expressed tran-
siently in COS-7 cells. In membranes of transfected cells the
wild type rFP-R protein was detected as a group of bands
above 53 kDa, which were absent from membranes of un-
transfected cells (Fig. 2). An identical pattern was seen with
the rFP-H81Q-R (Fig. 2) and all other mutant receptors (not
shown). These bands most likely represent receptor proteins in
which the three potential glycosylation sites in the N-terminal
domain and the third extracellular loop are glycosylated to
di¡erent extents. The bands with an apparent molecular
weight above 90 kDa most likely represent aggregates of re-
ceptor proteins. Such aggregates are frequently found with
GPCRs. If membranes of transfected cells were pretreated
with endoglycosidase F prior to electrophoretic separation
only one broad band appeared in the range of 41 kDa (Fig.
2), the calculated molecular mass of the non-glycosylated re-
ceptor protein. The expression levels of the wild-type rFP-R
and the ¢ve mutant receptors were estimated by densitometric
quanti¢cation of the Western blots (Fig. 3C). Expression lev-
els reached 50^80% of the receptor protein level found in
membranes transfected with the wild type receptor cDNA
(Fig. 3B).
3.3. PGF2K binding to the rFP-H81X receptors
Membranes of cells transfected with the wild type rFP-R or
the mutant receptors were incubated with 5 nM [3H]PGF2K
for 1 h at room temperature. Bound and unbound ligand were
separated by rapid vacuum ¢ltration. Unspeci¢c binding was
determined in the presence of a 2000-fold excess of unlabeled
PGF2K. Under these conditions, membranes of cells express-
ing the wild type rFP-R bound 586 fmol [3H]PGF2K/mg mem-
brane protein (Fig. 3A). Despite being expressed to a compa-
rable protein level (Fig. 3B) rFP-H81R-R, rFP-H81G-R and
rFP-H81A-R did not bind PGF2K at all. Only rFP-H81Q-R
and rFP-H81D-R bound PGF2K to a signi¢cant extent; how-
ever, [3H]PGF2K binding was merely 24% and 4%, respec-
tively, of the wild type receptor and thus was much less
than would have been expected from their protein expression
level of about 80% of the wild type receptor protein (Fig. 3B).
Reduced binding can most likely be attributed to a reduced
a⁄nity of the receptor proteins. The Kd of the wild type
receptor was determined to be about 22 nM (Fig. 4). Taking
into account the speci¢c binding at 5 nM PGF2K and the
protein expression level determined by Western blot analysis,
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Fig. 3. PGF2K binding and protein expression level of wild type
rFP- and rFP-H81X mutant receptors. A: Membranes of cells
transfected with the wild type rFP-R or the mutant receptors were
incubated with 5 nM [3H] PGF2K for 1 h at room temperature.
Bound and unbound ligand were separated by rapid vacuum ¢ltra-
tion. Unspeci¢c binding was determined in presence of a 2000-fold
excess of unlabelled PGF2K. B: Receptor expression determined den-
sitometrically with ImageQuant. Expression of wild type rFP-R was
set at 100%. Data are means þ S.E.M. from three independent trans-
fection experiments. C: Wild type and mutant receptors were de-
tected as described in the legend to Fig. 2.
Fig. 4. Determination of the a⁄nity of the rFP-R and the rFP-
H81Q-R by competition binding of [3H]PGF2K to membranes trans-
fected COS-7 cells. Binding of 5 nM [3H]PGF2K to membranes of
transfected cells was measured after 1 h at 20‡C in the presence of
the concentrations of unlabelled PGF2K indicated. [3H]PGF2K bind-
ing in the presence of 10 WM PGF2K was de¢ned as unspeci¢c bind-
ing. Maximal speci¢c binding was set at 100%. Values are means
þ S.E.M. of three di¡erent experiments performed in triplicate.
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one can estimate the Kd values of the mutant receptors to be
roughly 80 nM for the rFP-H81Q receptor and 540 nM for
the rFP-H81D receptor1. Due to the very low amount of
radioactivity bound to the rFP-H81D receptor it was not
possible to determine its a⁄nity by competition binding.
Therefore, a competition binding analysis was performed for
the rFP-H81Q mutant only. The Kd value of 48 nM deter-
mined by non-linear regression analysis of competition bind-
ing [17] (Fig. 4) agrees reasonably well with the value of
80 nM estimated from the single measurement at 5 nM
PGF2K. Both the rFP-R and the rFP-H81Q-R bound
PGF2KsPGD2sPGE2. The relative a⁄nities were compara-
ble, the absolute a⁄nities of the rFP-H81Q-R always ap-
peared to be two- to threefold lower (not shown).
3.4. pH optimum of PGF2K binding to rFP-R, rFP-H81Q-R
and rFP-H81D-R
It was unexpected that the rFP-H81D-R mutant bound
PGF2K to a signi¢cant extent. The Asp side chain carboxyl
group is largely dissociated at pH 6.2 and hence negatively
charged. Assuming that the carboxyl group of the prostanoid
should interact with Arg-291 in the seventh transmembrane
domain and therefore according to the calculated model
should come into contact with His-81 in the second trans-
membrane the negatively charged Asp in position 81 should
electrostatically repel the also negatively charged prostanoid
from the hypothetical binding pocket. Shifting the pH of the
binding bu¡er to acid pH values, where both the Asp side
chain and the prostanoid carboxyl group are undissociated
to a signi¢cant extent, should, therefore, increase PGF2K bind-
ing to the rFP-H81D-R mutant. In line with such a hypothesis
binding to the rFP-H81D-R mutant was strongly increased
when the pH was decreased to 4.5 (Fig. 5), a pH that corre-
sponds to the pK of the Asp side chain carboxyl group. In
contrast to the H81D mutant the wild type rFP-R and the
rFP-H81Q-R mutant showed a shallow pH optimum around
pH 5 with almost no decrease of binding at higher pH values
and a signi¢cant decrease of binding at lower pH values (Fig.
5). These data indicate that the amino acid at position 81 of
the rFP-R most likely is part of the binding pocket and pre-
sumably interacts with the carboxyl group of the prostanoid.
However, probably there is no need for a positively charged
amino acid side chain in position 81 of the second transmem-
brane domain of the FP receptor that could interact via ionic
interactions with the negatively charged carboxyl group of the
prostanoid, but rather a hydrogen bond donor is required in
this position that forms hydrogen bonds with the carboxyl
group oxygens of the prostanoid.
3.5. Conclusion
The experimental data support the hypothesis that the sec-
ond transmembrane domain of the rFP-R is part of the ligand
binding pocket. The data furthermore favor the assumption
that the His-81 faces towards the interior of this binding
pocket and might together with the Arg-291 in the seventh
transmembrane domain interact with the carboxyl group of
the prostaglandin. In the EP3-R the interaction between the
prostaglandin’s carboxyl group and the seventh transmem-
brane Arg has been characterized in detail. It was found
that both PGE2 and its uncharged methyl ester, which is a
hydrogen bond acceptor, were potent agonists for the EP3-R
while the complete lack of a carboxyl group led to a loss of
agonist activity. This indicates that agonist binding to the
EP3-R requires the carboxyl group but does not depend on
an ionic interaction of the carboxyl group with amino acids in
the binding pocket but is rather due to hydrogen bond for-
mation [24] between constituents of the binding pocket and
the carboxyl group of the prostaglandin. Assuming that the
interaction of the rFP-R with the carboxyl group of PGF2K is
similar to that of the EP3-R with PGE2, Arg-291 should form
hydrogen bonds with the carboxyl group of the prostaglandin.
The imidazole ring of the His-81 in the rFP-R could act as an
additional hydrogen bond donor in such a constellation. The
Gln side chain, which has a similar size as the His side chain,
could in part replace the His as a hydrogen bond donor. This
could be shown for the seventh transmembrane Arg of the
EP3K-R where mutation of the Arg residue to Gln did not
a¡ect high a⁄nity PGE2 binding whereas substitution to Leu
abolished PGE2 binding by the EP3-R [24]. The Asp side
chain in its uncharged form could probably still ful¢l the
hydrogen bond donor function in position 81 to some extent.
In contrast, the bulky and charged residue of a second Arg in
the rFP-H81R-R mutant probably distorts the binding pocket
thereby preventing PGF2K from binding. The lack of PGF2K
binding to the rFP-H81A-R and rFP-H81G-R mutants is in
line with the inability of the small aliphatic or missing side
chains to act as hydrogen bond donors.
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Fig. 5. pH optimum of PGF2K binding to rFP-R, rFP-H81Q-R and
rFP-H81D-R. [3H]PGF2K binding to membranes of COS-7 cells ex-
pressing the respective receptor protein was determined as described
in legend to Fig. 3 except that membranes were suspended and
binding assays were performed in a glycine-bu¡ered binding bu¡er
of the pH indicated. Values are means þ S.E.M. of three independ-
ent transfections in triplicate.
1 The estimate for the Kd of the mutant receptor (Kdmt) was calcu-
lated according to the following equations: (1) binding to the wild
type (wt) and mutant (mt) receptor at a given lingand concentration:
Bwt = BmaxwtU[L]/(Kdwt+[L]) and Bmt = BmaxmtU[L]/(Kdmt+[L]), re-
spectively. (2) Known parameters: Kdwt (determined by saturation
binding assays), Bmt = nUBwt (values determined in the single point
binding assay), Bmaxmt = mUBmaxwt (Bmax was assumed to be propor-
tional to the receptor protein level found by Western blot). (3) Since
the ligand concentration in both experiments was the same, the equa-
tions can be combined to calculate Kdmt : Kdmt = m/nU([L]+Kdwt)3[L].
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